Publications

PEER-REVIEWED PUBLICATIONS (in chronological order) (published 15 peer-reviewed research articles since the start of the tenure-track position at UC; * denotes the senior/corresponding authorship by the applicant):

1. Wang, S.-C.* PCNA – a ubiquitous house keeper or a potential therapeutic target? Trend in Pharmacological Sciences (TiPS) 35, 178-186, 2014 (impact factor 10.158)
2. Zhao H., Chen, M.-S., Lo, Y.-H., Waltz, S.E., Wang, J., Ho, P.C., Vasiliauskas, J., Plattner, R., Wang, Y.-L., Wang, S.-C.* The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer. Oncogene 33, 1429-1437, 2014. (impact factor 7.357)
3. Lo, Y.-H., Ho, P.-C., Chen, M.-S., Hugo, E., Ben-Jonathan, N., Wang, S.-C.* Phosphorylation at tyrosine 114 of Proliferating Cell Nuclear Antigen (PCNA) is required for adipogenesis in response to high fat diet. Biochem. Biophys. Res. Commun. 430, 43-48, 2013.
4. Yu, Y.-L., Chou, R.-H., Liang, J.-H., Chang, W.-J., Su, K. -J., Tseng, Y.- J., Huang, W.-C., Wang, S.- C., Hung, M.-C. Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-NegativeBreast Cancer Cells with Cell-Penetrating PCNA Peptides. PLoS ONE 8(4): e61362, 2013.
5. Cui, J., Germer, K., Wu, T., Wang, J., Luo, J., Wang, S.-C., Wang, Q., Zhang, X. Crosstalk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. Cancer Research 72,5625-5634, 2012. (impact factor 8.650)
6. Hsieh, T.H., Tsai, C.-F., Hsu, C.-Y., Kuo, P.-L., His, E., Suen, J.-L., Hung, C.-H., Lee, J.-N., Chai, C.- Y., Wang, S.-C , Tsai, E.-M. n-Butyl benzyl phthalate promotes breast cancer progression by inducing expression of lymphoid enhancer factor 1. PLoS ONE 7:e42750, 2012.
7. Lo, Y.-H., Ho, P.-C., Wang, S.-C.* Epidermal growth factor receptor (EGFR) protects proliferating cell nuclear antigen (PCNA) from cullin 4a (CUL4A)-mediated proteolysis. Journal of Biological Chemistry287, 27148-27157, 2012. PMC3411057 (impact factor 4.651)
8. Zhao, H., Lo, Y.-H., Ho, P.-H., Bedford, M.T., Hung, M.-C., and Wang, S.-C.* Interaction of proliferation cell nuclear antigen (PCNA) with the non-receptor tyrosine kinase c-Abl in cell proliferation and response to DNA damages in breast cancer cells. PLoS ONE 7(1): e29416. doi:10.1371/journal.pone.0029416, 2012. PMC3251568.
9. Hsieh, T.-H., Tsai, C.-F., Hsu, C.-Y., Kuo, P.-L., Lee, J.-N., Chai, C.-Y., Wang, S.-C*, Tsai, E.-M.*Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway. (*, co-corresponding authors) Journal of the Federation of American Societies for Experimental Biology (FASEB J) 26:778-787, 2012 (impact factor 5.704)
10. Ding, Q, Chang, C.-J., Xie, X., Xia, W., Yang, J.-Y., Wang, S.-C., Wang, Y., Xia, J., Chen, L., Cai, C., Li, H., Yen, C.-J., Kuo, H.-P., Lee, D.-F., Lang, J., Huo, L., Cheng, X., Chen, Y.-J., Li, C.-W., Jeng, L.- B., Hsu, J.-L., Li, L.-Y., Tan, A., Curley, S.A., Ellis, L.M., DuBois, R.N., Hung, M.-C. APOBEC3G promotes liver metastasis in orthotopic colorectal cancer mouse model and predicts human hepatic metastasis. Journal of Clinical Investigation 121:4526-4536, 2011. (impact factor 12.812)
11. Lo, Y.-H., Ho, P.-C., Zhao, H., and Wang, S.-C.* Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016). Anticancer Research 31:789- 795, 2011.
12. Zhao, H., Lo, Y.-H., Ma, L., Waltz, S.E., Gray, J.K., Hung, M.-C., Wang, S.-C.* Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth. Molecular Cancer Therapeutics 10:29-36,2011. (impact factor 5.599)
13. Zhao, H., Lo, Y.-H., Yu, L. and Wang, S.-C.* Overcoming resistance to fulvestrant (ICI182,780) by downregulating the c-ABL proto-Oncogene in breast cancer. Molecular Carcinogenesis 50:383-389,2011.
14. Zhao, H., Ou-Yang, F., Chen, I.-F., Hou, M.-F., Yuan, S.-S. F., Chang, H.-L., Lee, Y.-C., Plattner, R., Waltz, S., Ho, S.-M., Sims, J., and Wang, S.-C.* Enhanced resistance to tamoxifen by the c-ABLproto-oncogene in breast cancer. Neoplasia 12:214-223, 2010. (impact factor 5.470)
15. Wang, S.-C. and Hung, M.-C. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clinical Cancer Research 15: 6484-6489, 2009. (impact factor 7.837)
16. Nakagawa-Goto, K., Yamada, K., Nakamura, K., Chen, T.-H., Chiang, P.-C., Bastow, K. F., Wang, S.- C., Spohn, B., Hung, M.-C., Lee, F.-Y., Lee F.-C., and Lee, K.-H.. Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant - taxoid conjugates as novel cytotoxic agents.Bioorganic & Medicinal Chemistry Letters 17:5204-5209, 2007.
17. Wang, S.-C., Nakajima, Y., Yu, Y.-L., Xia, W., Chen, C.-T., Li, L.-Y., Hawke, D. H., Kobayashi, R., Hung, M.-C. Tyrosine phosphorylation controls PCNA function through protein stability. Nature Cell Biology 8:1359-1368, 2006. (impact factor 20.761)
18. Yu, Z, Xia, W., Wang, H., Wang, S.-C., Pan, Y., Kwong, K.Y., Hortobagyi, G.N. And Hung, M-C.Antitumor activity on an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. Molecular Carcinogenesis 45:667-675, 2006.
19. Xia, W.‡, Lien, H.-C.‡, Wang, S.-C.‡, Pan, Y., Sahin, A., Kuo, Y.-H., Chang, K.-J., Zhou, X., Wang, H., Yu, Z., Hortobagyi, G., Shi, D.-R., and Hung, M.-C. (‡, equally contributed) Expression of PEA3 and Lack of Correlation between PEA3 and HER-2/neu Expression in Breast Cancer. Breast Cancer Research and Treatment 98:295-301, 2006.
20. Chen, I-F., Ou-Yang, F., Hung, J-Y., Liu, J-C., Wang, H., Wang, S-C., Hou, M-F., Hortobagyi, G.N. and Hung, M-C. AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. Molecular Cancer Therapeutics 5: 1-7, 2006. (impact factor 5.599)
21. Wang, S.-C. and Hung, M.-C. Cytoplasmic/nuclear shuttling and tumor progression. Annals of the New York Academy of Sciences 1059:1-5, 2005.
22. Giri, DK., Ali-Seyed, M., Li, L-Y., Lee, D-F., Ling, P., Bartholomeusz, G., Wang, S.-C. and Hung, M-C.Endosomal transport of ErbB-2: a mechanism for nuclear entry of cell surface receptor. Molecular and Cellular Biology 25:11005-11018, 2005. (PMCID1316946) (impact factor 5.372)
23. Wang, S.-C. and Hung, M.-C. Finding the bEST routes to cancer. Cancer Biology & Therapy 3(11):e132-e133, 2004.
24. Wang, S.-C., Lien, H.-C., Xia, W., Chen, I.-F., Lo, H.-W., Wang, Z., Ali-Seyed, M., Bartholomeusz, G.,Ou-Yang, F., Giri, D.K., Hung, M.-C. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6, 251-261, 2004. (impact factor 24.755)
25. Makino, K., Day, C.-P., Wang, S.-C., Li, Y.M., Hung, M.-C. Upregulation of IKKa/IKKb by integrin- linked kinase is required for HER2/neu-induced NF-kB antiapoptotic pathway. Oncogene 23:3883- 3887, 2004.(impact factor 7.357)
26. Lee, C.M., Lo, H.-W., Shao, R.-P., Wang, S.-C., Xia, W., Gershenson, D.M., Hung, M.-C. Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy. Cancer Research 64:1788-1793, 2004. (impact factor 8.650)
27. Yan, D.H., Wen, Y., Su, L.K., Xia, W., Wang, S.C., Zhang, S., Gan, L., Lee, D.-F., Spohn B., Frey, J.A., Hortobagyi, G.N., Hung, M.C. A delayed chemically-induced tumorigenesis in Brca2 mutant mice. Oncogene 23:1896-1901, 2004. (impact factor 7.357)
28. Lee, C.M., Shvartsman, H., Deavers, M.T., Wang, S.-C., Xia, W., Schmandt, R., Bodurka, D. C., Atkinson, E.N., Malpica, A., Gershenson, D.M., Hung, M.-C., Lu, K.H. b-catenin nuclear localization is associated with grade in ovarian serous carcinoma. Gynecology Oncology 88:363-368, 2003.
29. Asada, S., Choi, Y., Yamada, M., Wang, S.-C., Hung, M.-C., Qin, J., Uesugi, M. External conctrol of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. Proceedings of the National Academy of Science USA (PNAS)99:12747-12752, 2002. (impact factor 9.737)
30. Wang, S.-C., Shao, R., Pao, A.Y., Zhang, S., Hung, M.-C., and Su, L.-K. Inhibition of cancer cell growth by BRCA2. Cancer Research 62:1311-1314, 2002. (impact factor 8.650)
31. Wang, S.-C. and Hung, M.-C. HER2 over-expression and cancer targeting. Seminars in Oncology28(5)(Suppl. 16):115-124, 2001.
32. Wang, S.-C., Zhang, L., Hortobagyi, G.N. and Hung, M.-C. Targeting HER-2: Recent developments and future directions for breast cancer patients. Seminars in Oncology 28(6) (Suppl. 18):21-29, 2001.
33. Zou, Y., Peng, H., Zhou, B., Wen, Y., Tsai, E.-M., Wang, S.-C., and Hung M.-C. Systemic tumor suppression by the pro-apoptotic gene bik Cancer Research 62:8-12, 2001. (impact factor 8.650)
34. Wang, S.-C., Makino, K., Su, L.-K., Pao, A.Y., Kim, J.S., Hung, M.-C. Ultraviolet irradiation induces BRCA2 protein depletion through a p53-independent and protein synthesis-dependent pathway.Cancer Research 61:2838-2842, 2001. (impact factor 8.650)
35. Tsai, E.-M.‡, Wang, S.-C.‡, Hung, M.-C. (‡, equally contributed) Akt activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Research 61:8390-8392, 2001. (impact factor 8.650)
36. Wang, S.-C., Makino, K., Xia, W., Kim, J.S., Im, S.-A., Peng, H., Mok, S.C., Singletary, S.E., Hung,M.-C. DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt- independent pathway. Oncogene 20:6960-6964, 2001. (impact factor 7.357)
37. Hung, M.-C. and Wang, S.-C. Suppressing HER-2/neu-mediated cell trans-formation by transcriptional repressors. Breast Disease 11:133-144, 2000.
38. Wang, S.-C. and Hung, M.-C. Transcriptional targeting of the HER-2/neu oncogene. Drugs of Today36(12):835-843, 2000.
39. Xing, X.‡, Wang, S.-C.‡, Xia, W., Zou, Y., Shao, R., Kwong, K.-Y., Yu, Z., Zhang, S., Miller, S., Huang, L., Hung, M.-C. (‡, equally contributed) The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nature Medicine 6:189-195, 2000. (impact factor 24.302)
40. Lo, S.-S., Lo, S.-H., Wang, S.-C., Hung, M.-C. Focal contacts formation is inhibited in cells transformed by p185neu. Molecular Carcinogenesis 25:150-154, 1999.
41. Su, L.-K., Wang, S.-C., Qi, Y., Luo, W., Hung, M.-C., Lin, S.-H. Characterization of BRCA2: temperature sensitivity of detection and cell-cycle regulated expression. Oncogene 17:2377-2381,1998. (impact factor 7.357)
42. Wang, S.-C., Lin, S.-H., Su, L.-K., Hung, M.-C. Changes in BRCA2 expression during progression of the cell cycle. Biochem. Biophys. Res. Commun., 234:247-251, 1997.

Book Chapters:

1. Hung, M.-C. and Wang, S-C. Transcriptional repression in cancer gene therapy: targeting HER-2/neuoverexpression as an example. In: Gene Therapy and Molecular Biology, Teni Boulikas (Ed.), vol. 3, pp. 3:1-11, Gene Therapy Press, Palo Alto, CA, 1998.
2. Hung, M.-C., Wang, S-C., and Hortobagyi, G. Targeting HER-2/neu-overexpressing cancer cells with transcriptional repressor genes delivered by cationic liposome. In: Cancer Gene Therapy Using Cationic Liposome: Preclinic and Clinic Studies, L. Huang, E. Wagner (Eds.). Academic Press, San Diego, CA, pp. 357-377, 1999.

Oral Presentattions

Mar. 28, 2007	“Regulation of PCNA Function by Tyrosine Phosphorylation”. Department of Environmental Health, Dr. Shuk-Mei Ho group meeting.
Apr. 6, 2007	“The Death of A Ring”. Department of Surgery Research Conference.
Apr. 11, 2007	“The Role of Proliferating Cell Nuclear Antigen (PCNA) in Cancer Progression and Chemotherapy”. Department of Surgery Surgical Grand Rounds.
May 2, 2007	“Regulation of PCNA function by tyrosine phosphorylation”. Department of Surgery, Dr. Susan Waltz Oncology Research Group meeting.
Jun. 15, 2007	“Nuclear Localization of EGFR and PCNA”. Oncology Retreat, Department of Surgery, Oncology Research Group, University of Cincinnati.
Oct. 10, 2007	“Tyrosine phosphorylation of PCNA and its potential role in chemosensitivity of cancer cells”. Hormonal Malignancies Program.
Oct. 25, 2007	“Tyrosine phosphorylation of PCNA – the potential role in chemosensitivity of cancer cells”. Department of Surgery, Dr. Susan Waltz Oncology Research Group meeting.
Nov. 14, 2007	“Tyrosine phosphorylation of PCNA and its potential role in chemosensitivity of cancer cells”. Department of Environmental Health, Dr. Shuk-Mei Ho group meeting.
Jan. 10, 2008	“Signaling regulation of PCNA function on the chromatin”. Department of Cell Biology Seminar Series.
Feb. 16, 2008	“Tyrosine kinases, PCNA, and signaling transduction”. Cell and Cancer Biology graduate program recruitment data blitz.
Feb. 20, 2008	“PCNA and receptor tyrosine kinase”. Department of Surgery, Dr. Susan Waltz Oncology Research Group meeting.
Apr. 23, 2008	“Signaling regulation of PCNA function on the chromatin”. Department of Environmental Health, Dr. Shuk-Mei Ho group meeting.
May 2, 2008	“Regulation of PCNA function by tyrosine phosphorylation”. Surgery Research Conference.
Nov. 10, 2008	“Interaction between c-Abl and PCNA”. Department of Surgery, Dr. Susan Waltz Oncology Research Group meeting.
Nov. 12, 2008	“Interaction between c-Abl and PCNA”. Department of Environmental Health, Dr. Shuk-Mei Ho group meeting.
Dec. 2, 2008	“Exploring the interface of cell proliferation and DNA damage response”. Department of Cancer and Cell Biology Annual Retreat.
Mar. 2, 2009	“PCNA tyrosine phosphorylation and breast cancer”. Cancer Center Pilot Grant progress report.
Jun. 1, 2009	“Exploring the interface of cell proliferation and DNA damage response”. Department of Biomedical Engineering, Dr. Peixuan Guo group meeting.
Dec. 11, 2009	“enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer”. Department of Environmental Health, Dr. Shuk-Mei Ho group meeting.
Dec. 17, 2009	“Interaction of tyrosine kinases in regulation of PCNA function”. Genome Instability group meeting.
Oct. 27, 2008	“Targeting PCNA”. Genome Research Institute (GRI) – Drug Development group.
Mar. 23, 2010	“Interaction of tyrosine kinases in regulation nof PCNA function”. Department of Cancer and Cell Biology Retreat.
`May 21, 2008	“Tyrosine phosphorylation of PCNA in cancer” and “Overcoming tamoxifen resistance in breast cancer”. Department of Cancer and Cell Biology Faculty meeting.
May 28, 2010	“The role of the proto-oncogene c-ABL in resistance to anti-estrogens”. Department of Environmental Health, Dr. Shuk-Mei Ho group meeting.
Nov. 12, 2010	“Regulation of cellular response to growth inhibition in breast cancer”. Department of Environmental Health, Dr. Shuk-Mei Ho group meeting.
Feb. 12, 2011	“Tyrosine kinases, PCNA, and signaling transduction”. Cell and Cancer Biology graduate program recruitment data blitz.
Mar. 29, 2011	“Estrogen signaling, breast cancer, and hormone therapy”. Participating speaker of the Department of Cancer and Cell Biology for a special presentation to Provost Ono and other institutional leaders.
Jul. 8, 2011	“Overcome breast cancer resistant to endocrine therapy”. Department of Environmental Health, Dr. Shuk-Mei Ho group meeting.
May 11, 2012	“Regulation of PCNA tyrosine phosphorylation in breast and prostate cancer”. Department of Environmental Health, Dr. Shuk-Mei Ho group meeting.
Dec. 6, 2012	“Role of PCNA phosphorylation in adipocyte differentiation and obesity”. UC Metabolic Diseases Institute, CLAS Thursday Morning Lipid Meeting.
Dec. 14, 2012	“Role of PCNA phosphorylation in adipocyte differentiation and obesity”. Department of Environmental Health, Dr. Shuk-Mei Ho group meeting.
Jan. 25, 2013	“Role of PCNA phosphorylation in adipocyte differentiation and obesity”. Genome Instability group meeting.
Feb. 23, 2013	“Tyrosine kinases, PCNA, and hormone resistance”. Breast Cancer Center of Excellence Retreat.
Sept. 26, 2013	“Signaling regulation of cell proliferation in cancer and obesity”. Cancer and Cell Biology Seminar Series.

External seminar presentations/session chair:

Oct. 16, 2008	University of Kentucky, Department of Molecular and Biomedical Pharmacology Seminar title - “Regulation of the Nuclear PCNA Sliding Clamp by Tyrosine Phosphorylation”.
Apr. 19, 2010	Late Breaking mini-symposium at AACR 2010 meeting Seminar title - “Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer”.
Nov. 20, 2010	2010 Kaohsiung International Cancer Symposium (Taiwan) Seminar title - “Regulation of cellular response to growth inhibition in breast cancer”.
May 19-20, 2012	14th Annual Midwest DNA Repair Symposium Session Chair - “Translesion Polymerases and Mutagenesis”.
April 7-9, 2014	NIEHS Core Center Meeting – Los Angeles, CA Seminar title - “Tyrosine phosphorylation of PCNA - a novel adipogenic signaling regulated by DEHP”